Starting GLP-1s on Medicaid in 2026: What to Expect

If you're on Medicaid and your doctor has just prescribed a GLP-1 or anti-obesity medication — Wegovy, Ozempic, Mounjaro, or another brand — 2026 is a meaningful year to be starting. Access has changed, and this guide walks you through what to expect: the process, the paperwork, the first few weeks, and how to track your progress.

What Is the CMS BALANCE Model?

In January 2026, the Centers for Medicare & Medicaid Services (CMS) formally announced the BALANCE Model — short for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth — a voluntary programme that opens the door for state Medicaid programmes to cover GLP-1 and anti-obesity medications for qualifying beneficiaries. State Medicaid participation opened on 1 May 2026.

Before this, most Medicaid plans only covered GLP-1 medications when prescribed for Type 2 diabetes, not for obesity on its own. The BALANCE Model treats obesity as a primary chronic condition and may open coverage for eligible enrollees who don't have a diabetes diagnosis.

Important caveat: BALANCE participation is voluntary, and as of May 2026, a limited number of state Medicaid programmes have enrolled. Before assuming you are covered, contact your state Medicaid office or prescriber to confirm your state is participating.

Note: CMS announced on 22 April 2026 that the Medicare Part D portion of BALANCE is delayed pending further evaluation. The Medicaid access pathway described in this article is unaffected.

Which GLP-1 and Related Medications May Be Covered?

The major GLP-1 and anti-obesity medications available in 2026 include:

• Semaglutide — Ozempic (diabetes indication) and Wegovy (obesity indication) — a GLP-1 receptor agonist
• Tirzepatide — Mounjaro (diabetes) and Zepbound (obesity) — a dual GIP/GLP-1 receptor agonist; its two-target mechanism produces stronger average weight loss (~22%) compared to pure GLP-1 medications (~15–18%)
• Liraglutide — Victoza (diabetes) and Saxenda (obesity) — a GLP-1 receptor agonist
• Dulaglutide — Trulicity (diabetes) — a GLP-1 receptor agonist

Coverage depends on your state, your plan, and which indication your prescription is written for. The key document is your formulary — the list of covered drugs for your specific Medicaid plan. Ask your pharmacist or log into your Medicaid benefits portal to check.

Prior Authorisation: What It Is and How to Prepare

Prior authorisation (PA) is the most common hurdle when starting a GLP-1 on Medicaid. It means your insurer must approve the prescription before it will cover the cost.

Common triggers for a PA request:

• GLP-1 prescribed for obesity rather than diabetes
• Brand-name medication when a generic alternative exists
• No documented history of other weight-management treatments

What your prescriber will typically submit:

• Your BMI (usually 30 or above, or 27+ with a related condition such as hypertension)
• A record of other treatments you've tried — dietary programmes, other medications
• Diagnosis codes supporting medical necessity
• A letter of medical necessity

Tip:Ask your prescriber's office whether they have a PA coordinator. The more complete the initial submission, the faster approval tends to go. Standard review times range from 3–15 business days, with shorter windows available under urgent review in many states.

If your PA is denied, you have the right to appeal. The denial must be provided in writing with a stated reason, and you typically have 30–90 days to file an appeal with additional evidence. Advocate-assisted appeals have a high success rate — don't stop at the first no.

Understanding Your Cost-Share

Even with Medicaid coverage, there may be a small cost-share:

• Standard Medicaid: Typically a $1–$4 copay per fill, or no copay below certain income thresholds
• Managed Care Medicaid: Varies by your specific plan — check your Summary of Benefits document
• Spend-down plans: GLP-1 prescriptions count toward your monthly incurred medical expenses

GLP-1 pens typically come in a 4-week supply. If you're being titrated — starting on a lower dose before stepping up — expect more frequent check-ins with your prescriber in the first few months.

Ways to reduce your out-of-pocket cost:

• Manufacturer patient assistance programmes — Novo Nordisk (Wegovy/Ozempic), Eli Lilly (Mounjaro/Zepbound), and others have patient support lines that can help with cost-sharing even when you have coverage
• 90-day fills— once you're stable on a dose, some plans allow 90-day fills that reduce your cost per day and the number of pharmacy trips
• Formulary tier— ask your prescriber if there's a medication on a preferred formulary tier (lower cost-share) that suits your clinical picture

What to Expect in the First Four Weeks

GLP-1 and related medications work gradually. The first few weeks are about your body adjusting — not dramatic weight loss. Here's a realistic picture.

Weeks 1–2:

• Appetite may feel noticeably reduced, or you may feel full more quickly than usual
• Nausea is the most common side effect, especially in the 12–24 hours after your injection — this usually improves within a few weeks
• Mild injection site reactions (redness, itching at the injection spot) are normal
• Some people experience fatigue, mild headaches, or constipation

Weeks 3–4:

• Appetite suppression tends to become more consistent
• Nausea typically eases as your body adjusts
• Most people see modest weight loss in the first month — typically under 1–2 kg, as you're still on a low starting titration dose. This is expected — the medication is not yet at its working dose, and that is by design

When to call your prescriber:

• Severe or persistent vomiting, or sharp abdominal pain
• Signs of low blood sugar (shakiness, sweating, confusion) if you're also on insulin or other diabetes medications
• Any significant change in vision

Most people tolerate GLP-1s well at the starting titration dose. The key is not rushing the dose escalation — the slow step-up exists for good reason.

What to Track from Day One

These medications work over months, not days. If you're not measuring, it's easy to feel like nothing is happening even when the trend is moving in the right direction.

Here's what's worth logging:

You don't need a spreadsheet. A GLP-1 tracker app handles all of this with a few taps — and having a complete record is useful when your PA comes up for renewal.

Questions Worth Asking at Your First Appointment

Don't leave without asking:

1. What dose am I starting on, and what's the titration schedule? GLP-1s and related medications are started low and stepped up over weeks or months to reduce side effects.
2. How long before I should expect to see changes? Set realistic expectations — most meaningful results show at 12–16 weeks.
3. What do I do if the nausea is bad? Timing the injection at night, staying hydrated, and eating small meals can help. Ask what level of nausea warrants a call.
4. Will this interact with my other medications? GLP-1s slow gastric emptying, which can affect how quickly other oral medications absorb.
5. Can your office handle the PA — and the appeal if it's denied? Most can; confirm the process upfront.
6. How do I get refills, and how far in advance? With prior auth, running out has a real cost — plan ahead.

Frequently Asked Questions

Last updated: May 2026. Coverage rules, plan formularies, and BALANCE Model state participation change frequently — always verify with your state Medicaid programme or prescriber.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your prescriber or a qualified healthcare professional before making changes to your medication or supplement regimen.